DUBLIN--(BUSINESS WIRE)--The "Endometriosis - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
According to research, the global market [that includes 7MM, Rest of Europe (RoE) and Rest of World (RoW)] of Endometriosis was USD 1,856 Million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Endometriosis from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
According to research, the prevalent cases of Endometriosis in 7 major markets was 13.8 Million in 2016 and, is expected to increase at a significant growth rate during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of Endometriosis i.e., 7.4 Million followed by United Kingdom.
The marketed drugs available for the treatment of Endometriosis mainly include Lupron (Abbvie), Visanne/Dienogest (Bayer Healthcare), Zoladex (AstraZeneca), Synarel (Pfizer) and Depo-SubQ. Detailed chapters for all of these drugs, along with the promising upcoming therapies such as Elagolix (Abbvie), Femitra (Endooceutics) etc. have been covered in the report.
- AbbVie Inc
- Bayer HealthCare Pharmaceuticals
- EndoCeutics Inc
Key Topics Covered:
1. Report Introduction
2. Endometriosis Market Overview at a Glance
3. Disease Background and Overview: Endometriosis
4. Epidemiology of Endometriosis in 7MM
5. Treatment Algorithm
6. Current Unmet Needs
7. Marketed Drugs
8. Emerging Therapies
9. Global Endometriosis: Country-Wise Market Analysis
10. Market Drivers
11. Market Barriers
13. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/985qgn/global?w=4